Andrew Left’s Citron Research Places $100 Price Target On Compass Pathways
Andrew Left of Citron Research today released a research paper on Compass Pathways (NASDAQ: CMPS), giving it a long term
Read moreAndrew Left of Citron Research today released a research paper on Compass Pathways (NASDAQ: CMPS), giving it a long term
Read moreIt appears that some authenticity and validation might be coming to the psychedelics space. Compass Pathways, a UK startup focused
Read more